Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 3 1Phase 2 1

Status

Recruiting 21Unknown 18Completed 17Active not recruiting 15Not yet recruiting 7Terminated 4Withdrawn 2Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Head & Neck 1Dermatologic 1

Conditions

Eyelid Squamous Cell Carcinoma 1

Interventions

Paclitaxel 3Surgical Procedures, Operative 2Radiotherapy 2Oxaliplatin 2Magnetic Resonance Spectroscopy 2Fluorouracil 2Doxorubicin 2Cyclophosphamide 2titanium silicide 1sargramostim 1exemestane 1eribulin 1cemiplimab 1Vincristine 1Taxes 1Tamoxifen 1Surveys and Questionnaires 1Specimen Handling 1S 1 (combination) 1Rituximab 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Image-Guided 1Prednisone 1Prednisolone 1Passive Cutaneous Anaphylaxis 1Neoadjuvant Therapy 1Morphine 1Methylprednisolone 1Methotrexate 1Methods 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Suspended × Radiotherapy, Intensity-Modulated × Clear all
NCT06568172 2026-05-13

Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer

National Cancer Institute (NCI)

Phase 3 Suspended
420 enrolled
DermatologicHead & NeckSarcoma

Eyelid Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡